Congenital diseases are disorders in a newborn due to certain genetic factors (and sometimes in association with the environment) that often results in malformations or underdeveloped organs. Congenital Heart Diseases (CHD) results in malformed or undeveloped heart that presents in a newborn with breathing and circulation disorders. According to Lancet medical journal, CHD caused death of 0.22 million individuals and newborns globally in the year 2010. CHD was earlier erroneously associated with premature births, the association has no direct correlation with all forms of CHD and is mainly one of the many factors that can cause it. The genetic factors causing CHD consist of chromosomal errors in fertilization and the following meiotic division, these include: large chromosomal defects in trisomal chromosomes; small chromosomal defects like microdeletion of long/short arm of chromosome and random/environmentally induced mutation of heart muscle cell proteins, or associated proteins etc. The environmental factors like rubella infections, thalidomide drugs, metals (lithium, lead, mercury, etc), chronic illness in the mother (systemic lupus, diabetes, phenylketonuria, etc). Embryological changes, hormonal changes in the mother and certain birth deficiencies can also cause CHD and other birth defects in children. Besides these, according to some medical research reports, maternal obesity increased the chances of CHD in newborns; obesity was shown to increase the risk of previously hidden genetic traits of CHD in the new born children of such obese mothers.
Highlights
The global Congenital Heart Diseases market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The treatment of CHD varies from case to case; genetic testing/screening is mandatory in case the doctor suspects a genetic cause for the disease, in developed countries this is done for all newborns. The next step would be surgery or drug treatment, again this depends upon the severity of the condition. In most cases CHD presents itself as serious conditions with high risk of complications, hence surgery is the most followed procedure. In certain disorders like ASD a pediatric surgeon may ask the parents of a CHD child to wait for the child’s growth as ASD is known to disappear gradually, a surgery is performed if ASD persists after the child’s growth. Certain cases also require multiple surgeries and stenting in order to restore a malformed tract in the lungs, etc. Drugs like diuretics are given to regulate vasoconstriction that alleviates deoxygenation and helps remove toxins from the body, besides reducing the heartbeat.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Congenital Heart Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Congenital Heart Diseases.
The Congenital Heart Diseases market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Congenital Heart Diseases market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Congenital Heart Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Abbott Laboratories
Eli Lilly
Ranbaxy Pharmaceutical
Segment by Type
Hypoplasia
Obstructive
Septal Defects
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Congenital Heart Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Âé¶¹Ô´´ Analysis by Type
1.2.1 Global Congenital Heart Diseases Âé¶¹Ô´´ Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hypoplasia
1.2.3 Obstructive
1.2.4 Septal Defects
1.3 Âé¶¹Ô´´ by Application
1.3.1 Global Congenital Heart Diseases Âé¶¹Ô´´ Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Congenital Heart Diseases Âé¶¹Ô´´ Perspective (2018-2029)
2.2 Congenital Heart Diseases Growth Trends by Region
2.2.1 Global Congenital Heart Diseases Âé¶¹Ô´´ Size by Region: 2018 VS 2022 VS 2029
2.2.2 Congenital Heart Diseases Historic Âé¶¹Ô´´ Size by Region (2018-2023)
2.2.3 Congenital Heart Diseases Forecasted Âé¶¹Ô´´ Size by Region (2024-2029)
2.3 Congenital Heart Diseases Âé¶¹Ô´´ Dynamics
2.3.1 Congenital Heart Diseases Industry Trends
2.3.2 Congenital Heart Diseases Âé¶¹Ô´´ Drivers
2.3.3 Congenital Heart Diseases Âé¶¹Ô´´ Challenges
2.3.4 Congenital Heart Diseases Âé¶¹Ô´´ Restraints
3 Competition Landscape by Key Players
3.1 Global Top Congenital Heart Diseases Players by Revenue
3.1.1 Global Top Congenital Heart Diseases Players by Revenue (2018-2023)
3.1.2 Global Congenital Heart Diseases Revenue Âé¶¹Ô´´ Share by Players (2018-2023)
3.2 Global Congenital Heart Diseases Âé¶¹Ô´´ Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Congenital Heart Diseases Revenue
3.4 Global Congenital Heart Diseases Âé¶¹Ô´´ Concentration Ratio
3.4.1 Global Congenital Heart Diseases Âé¶¹Ô´´ Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Congenital Heart Diseases Revenue in 2022
3.5 Congenital Heart Diseases Key Players Head office and Area Served
3.6 Key Players Congenital Heart Diseases Product Solution and Service
3.7 Date of Enter into Congenital Heart Diseases Âé¶¹Ô´´
3.8 Mergers & Acquisitions, Expansion Plans
4 Congenital Heart Diseases Breakdown Data by Type
4.1 Global Congenital Heart Diseases Historic Âé¶¹Ô´´ Size by Type (2018-2023)
4.2 Global Congenital Heart Diseases Forecasted Âé¶¹Ô´´ Size by Type (2024-2029)
5 Congenital Heart Diseases Breakdown Data by Application
5.1 Global Congenital Heart Diseases Historic Âé¶¹Ô´´ Size by Application (2018-2023)
5.2 Global Congenital Heart Diseases Forecasted Âé¶¹Ô´´ Size by Application (2024-2029)
6 North America
6.1 North America Congenital Heart Diseases Âé¶¹Ô´´ Size (2018-2029)
6.2 North America Congenital Heart Diseases Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Congenital Heart Diseases Âé¶¹Ô´´ Size by Country (2018-2023)
6.4 North America Congenital Heart Diseases Âé¶¹Ô´´ Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Congenital Heart Diseases Âé¶¹Ô´´ Size (2018-2029)
7.2 Europe Congenital Heart Diseases Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Congenital Heart Diseases Âé¶¹Ô´´ Size by Country (2018-2023)
7.4 Europe Congenital Heart Diseases Âé¶¹Ô´´ Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Congenital Heart Diseases Âé¶¹Ô´´ Size (2018-2029)
8.2 Asia-Pacific Congenital Heart Diseases Âé¶¹Ô´´ Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Congenital Heart Diseases Âé¶¹Ô´´ Size by Region (2018-2023)
8.4 Asia-Pacific Congenital Heart Diseases Âé¶¹Ô´´ Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Congenital Heart Diseases Âé¶¹Ô´´ Size (2018-2029)
9.2 Latin America Congenital Heart Diseases Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Congenital Heart Diseases Âé¶¹Ô´´ Size by Country (2018-2023)
9.4 Latin America Congenital Heart Diseases Âé¶¹Ô´´ Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Congenital Heart Diseases Âé¶¹Ô´´ Size (2018-2029)
10.2 Middle East & Africa Congenital Heart Diseases Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Congenital Heart Diseases Âé¶¹Ô´´ Size by Country (2018-2023)
10.4 Middle East & Africa Congenital Heart Diseases Âé¶¹Ô´´ Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Congenital Heart Diseases Introduction
11.1.4 Pfizer Revenue in Congenital Heart Diseases Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Detail
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Congenital Heart Diseases Introduction
11.2.4 Abbott Laboratories Revenue in Congenital Heart Diseases Business (2018-2023)
11.2.5 Abbott Laboratories Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Congenital Heart Diseases Introduction
11.3.4 Eli Lilly Revenue in Congenital Heart Diseases Business (2018-2023)
11.3.5 Eli Lilly Recent Development
11.4 Ranbaxy Pharmaceutical
11.4.1 Ranbaxy Pharmaceutical Company Detail
11.4.2 Ranbaxy Pharmaceutical Business Overview
11.4.3 Ranbaxy Pharmaceutical Congenital Heart Diseases Introduction
11.4.4 Ranbaxy Pharmaceutical Revenue in Congenital Heart Diseases Business (2018-2023)
11.4.5 Ranbaxy Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Pfizer
Abbott Laboratories
Eli Lilly
Ranbaxy Pharmaceutical
Ìý
Ìý
*If Applicable.